| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0805 |
| Trial ID | ChiCTR1900024035 |
| Disease | Multiple Myeloma |
| Altered gene | CD19|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD19 CAR-T cells |
| Co-treatment | lenalidomide |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | An open, single-center, single-arm clinical study of through lenalidomide combined with infusion of anti-BCMA CAR-T and anti-CD19 CAR-T therapy for relapsed and refractory multiple myeloma |
| Year | 2019 |
| Country | China |
| Company sponsor | the Affiliated Hospital of Xuzhou Medical University |
| Cohort 1 | |||||
|
|||||